CYP19A1 and invasive breast carcinoma: Greater prevalence [3], frequency (6 vs. 3.1 per 24 h [4]), and severely troubling VMS (quite or extremely bothered 55.4% vs. 12.1% [5]) have been reported by a greater proportion of women treated for BrCa than among those without a BrCa history, particularly among those taking aromatase inhibitors (AIs) [6, 7] or tamoxifen [8] or experiencing treatment-induced menopause [9, 10].